Details of the Drug
General Information of Drug (ID: DMDOHRF)
Drug Name |
2-HYDROXY-3,5-DIIODOBENZOIC ACID
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3,5-DIIODOSALICYLIC ACID; 133-91-5; 2-Hydroxy-3,5-diiodobenzoic acid; 3,5-Diiodo-2-hydroxybenzoic acid; Benzoic acid, 2-hydroxy-3,5-diiodo-; 2-Hydroxy-3,5-diiodobenzoate; 3,5-Diiodosalicylate; 2-Hydroxy-3,5-diiodobenzenecarboxylic acid; 2-HYDROXY-3,5-DIIODO-BENZOIC ACID; Salicylic acid, 3,5-diiodo-; NSC 6303; Benzoic acid, 3,5-diiodo-2-hydroxy-; UNII-1496OH15B6; 3,5-Diiodosalicylicacid; EINECS 205-124-0; BRN 2615358; AI3-33355; NSC6303; DHZVWQPHNWDCFS-UHFFFAOYSA-N; MFCD00002444; 1496OH15B6; DIU; rarechem al be 0656; ACMC-1BPSO
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 389.91 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||